|
|
阿帕替尼治疗晚期肝癌的研究进展
|
Abstract:
随着对肝癌发病机制研究的不断推进，晚期肝癌的治疗已经是化疗联合靶向药物，免疫联合药物的综合治疗时代。阿帕替尼是一种新型口服小分子酪氨酸激酶抑制剂，已被用于晚期肝癌的临床治疗中，并显示出较好的抗肿瘤效应及较低的不良反应，目前，阿帕替尼在恶性肿瘤抗血管生成靶向治疗的应用价值越来越高，未来将为晚期肝癌的治疗提供新的思路。
With the continuous advancement of the research on the pathogenesis of liver cancer, the treatment of advanced liver cancer has become a comprehensive era of chemotherapy combined with targeted drugs and immunotherapy combined with drugs. Path for he is a new kind of oral small molecule tyrosine kinase inhibitor, has been used in clinical treatment of advanced liver cancer, and showed good antitumor effect and lower adverse reactions, at present, the path for Nepal in targeted therapy of malignant tumor anti-angiogenesis application value is higher and higher, the future will provide new train of thought for the treatment of advanced liver cancer.
| [1] | Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654 |
| [2] | Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T., Galle, P., Seitz, J.F., Borbath, I., H？ussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J. and SHARP Investigators Study Group (2008) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390.
https://doi.org/10.1056/NEJMoa0708857 |
| [3] | Qin, S., Bai, Y., Lim, H.Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.S., Bhudhisawasdi, V., Kang, W.K., Zhou, Y., Lee, J. and Sun, Y. (2013) Randomized, Multicenter, Open-Label Study of Oxaliplatin plus Fluorouracil/Leucovorin versus Doxorubicin as Palliative Chemotherapy in Patients with Advanced Hepatocellular Carcinoma from Asia. Journal of Clinical Oncology, 31, 3501-3508. https://doi.org/10.1200/JCO.2012.44.5643 |
| [4] | Kong, S.Y., Park, J.W., Lee, J.A., Park, J.E., Park, K.W., Hong, E.K. and Kim, C.M. (2007) Association between Vascular Endothelial Growth Factor Gene Polymorphisms and Survival in Hepatocellular Carcinoma Patients. Hepatology, 46, 446-455. https://doi.org/10.1002/hep.21720 |
| [5] | 闫东, 曾辉英, 史仲华, 等. 甲磺酸阿帕替尼治疗中晚期肝细胞癌伴发乙型肝炎后肝硬化患者的临床疗效及安全性研究[J]. 中国肿瘤临床与康复, 2018, 25(2): 129-131. |
| [6] | Jain, R.K. (2014) Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell, 26, 605-622. https://doi.org/10.1016/j.ccell.2014.10.006 |
| [7] | Folkman, J., Merler, E., Abernathy, C. and Williams, G. (1971) Isolation of a Tumor Factor Responsible for Angiogenesis. Journal of Experimental Medicine, 133, 275-288. https://doi.org/10.1084/jem.133.2.275 |
| [8] | Lakshmikanthan, S., Sobczak, M., Li, C.S., Shaw, L. and Grant, M.B., Chrzanowska-Wodnicka, M. (2018) Rap1B Promotes VEGF-Induced Endothelial Permeability and Is Required for Dynamic Regulation of the Endothelial Barrier. Journal of Cell Science, 131, jcs207605. https://doi.org/10.1242/jcs.207605 |
| [9] | Shen, K., Ji, L., Gong, C., Ma, Y., Yang, L., Fan, Y., Hou, M. and Wang, Z. (2012) Notoginsenoside Ft1 Promotes Angiogenesis via HIF-1α Mediated VEGF Secretion and the Regulation of PI3K/AKT and Raf/MEK/ERK Signaling Pathways. Biochemical Pharmacology, 84, 784-792. https://doi.org/10.1016/j.bcp.2012.05.024 |
| [10] | Scott, L.J. (2018) Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. Drugs, 78, 747-758.
https://doi.org/10.1007/s40265-018-0903-9 |
| [11] | Tian, S., Quan, H., Xie, C., et al. (2011) YN968D1 Is a Novel and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase with Potent Activity in Vitro and in Vivo. Cancer Science, 102, 1374-1380.
https://doi.org/10.1111/j.1349-7006.2011.01939.x |
| [12] | He, X., Huang, Z., Liu, P., Li, Q., Wang, M., Qiu, M., Xiong, Z. and Yang, S. (2020) Apatinib Inhibits the Invasion and Metastasis of Liver Cancer Cells by Downregulating MMP-Related Proteins via Regulation of the NF-κB Signaling Pathway. BioMed Research International, 2020, Article ID: 3126182. https://doi.org/10.1155/2020/3126182 |
| [13] | Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C., Jia, Y., Shi, J., Zhang, L., Liu, X., Qiao, M., Chen, X., Su, C., Yu, H., Zhou, C., Zhang, J., Camidge, D.R. and Hirsch, F.R. (2019) Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Cancer Immunology Research, 7, 630-643. https://doi.org/10.1158/2326-6066.CIR-17-0640 |
| [14] | Ding, J., Chen, X., Gao, Z., Dai, X., Li, L., Xie, C., Jiang, H., Zhang, L. and Zhong, D. (2013) Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in Humans. Drug Metabolism & Disposition, 41, 1195-1210. https://doi.org/10.1124/dmd.112.050310 |
| [15] | Yang, C. and Qin, S. (2018) Apatinib Targets both Tumor and Endothelial Cells in Hepatocellular Carcinoma. Cancer Medicine, 7, 4570-4583. https://doi.org/10.1002/cam4.1664 |
| [16] | Zhong, N., Zhuang, W., Huang, Q., Wang, Q. and Jin, W. (2021) Apatinib Inhibits the Growth of Small Cell Lung Cancer via a Mechanism Mediated by VEGF, PI3K/Akt and Ki-67/CD31. Journal of Cellular and Molecular Medicine, 25, 10039-10048. https://doi.org/10.1111/jcmm.16926 |
| [17] | Qin, S., Li, Q., Gu, S., Chen, X., Lin, L., Wang, Z., Xu, A., Chen, X., Zhou, C., Ren, Z., Yang, L., Xu, L., Bai, Y., Chen, L., Li, J., Pan, H., Cao, B., Fang, W., Wu, W., Wang, G., Cheng, Y., Yu, Z., Zhu, X., Jiang, D., Lu, Y., Wang, H., Xu, J., Bai, L., Liu, Y., Lin, H., Wu, C., Zhang, Y., Yan, P., Jin, C. and Zou, J. (2021) Apatinib as Second-Line or Later Therapy in Patients with Advanced Hepatocellular Carcinoma (AHELP): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Gastroenterology and Hepatology, 6, 559-568.
https://doi.org/10.1016/S2468-1253(21)00109-6 |
| [18] | Yuan, G.S., He, W.M., Hu, X.Y., Li, Q., Zang, M.Y., Cheng, X., Huang, W., Ruan, J., Wang, J.J., Hou, J.L. and Chen, J.Z. (2021) Clinical Efficacy and Safety Analysis of Camrelizumab Combined with Apatinib as a Second-Line Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Chinese Journal of Hepatology, 29, 326-331. |
| [19] | Li, J., Zhao, X., Chen, L., Guo, H., Lv, F., Jia, K., Yv, K., Wang, F., Li, C., Qian, J., Zheng, C. and Zuo, Y. (2010) Safety and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor YN968D1 in Patients with Advanced Malignancies. BMC Cancer, 10, Article No. 529. https://doi.org/10.1186/1471-2407-10-529 |
